By directly targeting TRIB1, miR-101-3p and miR-132-3p control the inflammatory profile of human primary macrophages and prostate cancer cells, as exemplified by enhancing the expression and secretion of pro-inflammatory chemokine, interleukin-8. Here, CXCL8 is linked to prostate carcinoma.